SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 — Cytokinetics, Incorporated (NASDAQ: CYTK) announced that MYQORZO® (aficamten) has received approval from the China National Medical Products Administration (NMPA) for the treatment of adults with New York Heart Association (NYHA) Class II–III obstructive hypertrophic cardiomyopathy (oHCM). The approval authorizes MYQORZO to improve exercise capacity and disease-related symptoms, marking a major regulatory milestone for this first-in-class cardiac myosin inhibitor in one of the world’s largest pharmaceutical markets.
Science Significance
The approval of MYQORZO highlights a major scientific advance in the treatment of hypertrophic cardiomyopathy, a genetically driven cardiovascular disease characterized by myocardial hypercontractility and impaired ventricular filling. MYQORZO is a selective, small-molecule cardiac myosin inhibitor designed to directly modulate the underlying disease mechanism by reducing excessive actin–myosin cross-bridge formation during the cardiac cycle. Unlike symptomatic therapies, MYQORZO addresses sarcomere-level dysfunction, offering a targeted, disease-modifying approach. Its clinical validation in pivotal Phase 3 studies reinforces the growing role of precision pharmacology and muscle biology in cardiovascular drug innovation.
Regulatory Significance
From a cGxP perspective, NMPA approval represents a highly rigorous regulatory endorsement of MYQORZO’s quality, safety, and clinical efficacy. The decision reflects successful alignment with global pharmaceutical development standards, including robust clinical trial execution, validated manufacturing processes, and comprehensive pharmacovigilance planning. MYQORZO previously received Breakthrough Therapy Designation, underscoring its therapeutic importance. The China approval positions the product alongside ongoing FDA review in the United States and a positive opinion from the EMA’s CHMP, demonstrating Cytokinetics’ ability to navigate multi-regional regulatory frameworks under stringent GxP compliance expectations.
Business Significance
Advertisement
Commercially, the approval activates a $7.5 million milestone payment to Cytokinetics under its licensing and collaboration agreement for Greater China and establishes eligibility for additional development and commercial milestones totaling up to $142.5 million, along with tiered royalties on net sales. Entry into the Chinese market significantly expands MYQORZO’s global footprint and reinforces Cytokinetics’ strategy to build a cardiovascular-focused pharmaceutical franchise. For industry stakeholders, this milestone reflects the strong commercial potential of mechanism-driven cardiology drugs in regulated, high-growth markets.
Patients’ Significance
For patients living with obstructive hypertrophic cardiomyopathy, the approval represents access to a novel oral therapy capable of improving functional capacity, symptom burden, and daily quality of life. oHCM is associated with shortness of breath, chest pain, syncope, arrhythmias, and risk of sudden cardiac death, often limiting patients’ ability to engage in normal activities. MYQORZO offers a non-surgical, pharmacological option that directly targets disease pathology, reducing reliance on invasive procedures and long-term symptom management alone. The approval is particularly significant in China, where HCM remains underdiagnosed and undertreated.
Policy Significance
At the policy level, MYQORZO’s approval supports evolving healthcare priorities focused on innovation-driven access to advanced cardiovascular therapies. It aligns with regulatory efforts to accelerate the availability of high-impact medicines for serious, chronic diseases while maintaining rigorous quality and safety standards. The decision also highlights progress in international regulatory convergence, where data generated through global clinical development programs supports approvals across multiple jurisdictions. For policymakers and regulators, MYQORZO exemplifies how science-based regulatory pathways can enable timely patient access without compromising compliance or public health safeguards.
The NMPA approval of MYQORZO® (aficamten) marks a defining moment for Cytokinetics and for patients with obstructive hypertrophic cardiomyopathy in China. By combining cutting-edge muscle biology science, robust clinical evidence, and stringent cGxP-compliant regulatory execution, MYQORZO sets a new benchmark for cardiovascular pharmaceutical innovation. As regulatory decisions progress in other major markets, this milestone reinforces the role of globally harmonized quality, clinical, and regulatory standards in delivering transformative therapies to patients worldwide.
Source: cytokinetics press release
